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Abstract
Background and aims: Anxiety and depression are prevalent in patients with inflammatory 
bowel diseases (IBD), especially during IBD flares. IBD therapies can profoundly affect 
the mood of patients with IBD. We aimed to determine the long-term impact of anti-tumor 
necrosis factor (anti-TNF) and immunomodulators (IM) on anxiety and depressive symptoms 
in IBD patients.
Methods: We compared three treatment groups with IM only (group A), anti-TNF ± IM (group 
B) and no such therapy (group C). Patients completed the hospital anxiety and depression 
scale (HADS) at 1 year, 3 years, and 5 years after start of treatment.
Results: In total, 581 patients with IBD (42.9% Crohn’s disease, 57.1% ulcerative colitis/IBD 
unclassified) participated in this study. Effects of treatment were analyzed in a mixed effects 
model, with and without correction for confounders. Compared with group C, group B showed 
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Introduction
Inflammatory bowel disease (IBD) refers to a 
chronic relapsing inflammatory condition with 
the main subtypes ulcerative colitis (UC), IBD 
unclassified (IBDU) and Crohn’s disease (CD). 
Besides gastrointestinal symptoms, IBD is associ-
ated with a clinically relevant psychosocial bur-
den,1–6 with up to three times higher rates of 
depressive symptoms and anxiety in IBD patients 
compared with the general population.5,7–9
In IBD patients with moderate-to-severe disease 
activity, treatment with anti-tumor necrosis factor 
(anti-TNF) blocking agents, immunomodula-
tors (IM) or systemic corticosteroids is recom-
mended.10 While systemic corticosteroids can 
trigger depressive symptoms and anxiety, this 
medication can also improve patient mood.6,11,12 
Specifically, symptoms of depression and anxiety 
improved under therapy with anti-TNF therapy in 
patients with different chronic conditions, includ-
ing inflammatory diseases.13–16 One study sug-
gested that a reduction in depression in patients 
with IBD treated with infliximab for 4 weeks could 
be due to an improvement of disease activity.6
Depressive symptoms and anxiety are about twice 
as frequent in IBD patients with active versus inac-
tive disease,17 yet this relationship has been dis-
cussed controversially,18 with no causal link 
established to date.19–22 On the other hand, symp-
toms of depression and anxiety have been linked 
to more severe IBD symptoms, increased hospi-
talization rates,23 and lower adherence to treat-
ment,24 including anti-TNF therapy.25 Data from 
the Swiss-IBD cohort study (SIBDCS) showed a 
significant association between depressive symp-
toms and anxiety with clinical recurrence over 
time for all patients with IBD,26 in agreement with 
other studies.4 However, the complexity of the 
interplay of anti-TNF treatment with mood and 
the disease course has not yet been disentangled.
Using SIBDCS data, we analyzed the effects of 
anti-TNF therapy on depressive symptoms and 
anxiety during the course of IBD in patients with 
flares and quiescent disease. We hypothesized 
that treatment with anti-TNF ± immuno-modu-
latory therapy would result in clinically relevant 
changes in anxiety and depressive symptoms 
when compared with immunomodulatory ther-
apy only or none of these therapies. We further 
hypothesized that these effects would remain 
robust in a fully corrected multivariable analysis.
Methods
Study design and population
We analyzed prospectively data obtained from the 
SIBDCS, a nationwide registry, which started 
enrollment of IBD patients in 2006. For the lon-
gitudinal analysis, we considered all patients who 
were enrolled into SIBDCS between 2006 and 
2018. We compared three treatment groups: 
group A (immuno-modulatory therapy only 
for at least 2.5 years), group B (anti-TNF 
therapy ± immuno-modulatory therapy for at 
least 2.5 years), group C (no anti-TNFs, no 
immuno-modulatory therapy and follow up of at 
least 2.5 years). Immunomodulatory therapy was 
defined as either azathioprine, 6-mercaptopurine, 
a significant treatment-related improvement in both anxiety and depressive symptoms within 
the first 2.5 years and also thereafter. Group A showed a significant long-term improvement 
of anxiety and both short-term and long-term improvement in depressive symptoms. The 
significance of these results was maintained after correction for confounders, including 
corticosteroid treatment. Additionally, both groups A and B showed a significant decrease in 
disease activity in the first 2.5 years after start of treatment and also thereafter. Anti-TNF and 
IM treatment were associated with a similarly significant decrease in anxiety and depressive 
symptoms over an observation period of up to 5 years.
Conclusion: Besides a clear benefit for disease activity, anti-TNF and IM apparently improve 
the mood of patients with IBD.
Keywords: anti-TNF, anxiety, depressive symptoms, hospital anxiety and depression scale, 
immune-modulatory therapy, inflammatory bowel disease, mood, psychosocial factors
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or methotrexate. Anti-TNF therapy was defined 
as either infliximab, adalimumab, certolizumab 
pegol, or golimumab. Local or systemic steroid 
treatment was allowed in all groups (A–C) and 
steroid used was assessed across groups A–C.
Only patients who filled the psychosocial question-
naire: (a) before therapy (groups A, B) or within 
180 days after enrollment (group C), (b) for a sec-
ond measurement between 180 and 540 days after 
having started the therapy (groups A, B) or enroll-
ment (group C), and (c) for a third measurement 
at least one more time more than 900 days and/or 
for a fourth measurement more than 1600 days 
after start of therapy/after enrollment were 
included. For group C, which had no start with 
ant-TNF therapy and/or IM, we selected the time 
point of enrolment for the start of the analysis.
Time-point for data export was 29 October 2018. 
Multiple variables were extracted from the SIBDCS 
database, which are listed in the Supplemental 
material. For the follow-up evaluation and meas-
urements, annual follow-up questionnaires were 
analyzed. The reporting of this study conforms to 
the STROBE statement (see Supplemental mate-
rial for Strobe Checklist for cohort studies).27
For each patient in group A or B, the start of the 
analysis (baseline) was determined by the day 
either immunomodulatory therapy and/or anti-
TNF therapy treatment was first recorded in the 
SIBDC database. We used follow-up data up to 
5 years later for the follow-up analyses. If, during 
follow up, the other medication (either immuno-
modulatory therapy or anti-TNF therapy) was 
started, the patient was considered a group B 
patient. Patients from groups A–C were excluded 
from the study if a treatment in group A and B or 
no treatment in group C were not consistently 
documented until the end of follow up. In three 
patients in group C, vedolizumab was started at 
the end of the observation period. No tofacitinib 
and no ustekinumab was used in our patients. 
Specifically, patients qualified for group C only if 
neither immunomodulatory therapy nor anti-
TNF therapy treatment had been recorded dur-
ing follow up. Intermittent local or systemic 
steroid treatment was not an exclusion criterion, 
but was accounted for in the multivariable model.
After an initial assessment at the study entry, 
symptoms of depression and anxiety were assessed 
at 1 year (180–540 days), 3 years (900–1599 days), 
and 5 years (⩾1600 days) after start of treatment 
(or enrollment in group C).
Psychometric measures
The hospital anxiety and depression scale (HADS) 
is a self-assessment scale to rate mood in outpa-
tients.28 Details of psychometric measures can be 
found in the Supplemental material.
Statistical analyses
The p values for group differences within varia-
bles were calculated using Mann–Whitney U, 
Kruskall–Wallis, Chi-squared test, or Fisher’s 
exact test, respectively, where appropriate. A 
two-sided p value of < 0.05 was considered as sta-
tistically significant. For all statistical analyses, 
STATA was used.
For the multivariable analysis, we performed linear 
mixed model regression analyses. Our models dis-
tinguish time dependent effects in all patients, 
short-term (⩽2.5 years) and long-term (>2.5 years) 
effects according to therapy as well as patient spe-
cific trends for anxiety or depression at baseline 
and changes over time (random effects); details 
can be found in the Supplemental material.
Disease activity was measured by the Crohn’s dis-
ease activity index (CDAI; stable disease 
CDAI < 150 for CD) and the Modified Truelove 
and Witts activity index (MTWAI) for UC. 
For MTWAI we used 2 categories: active 
(MTWAI⩾3) and remission (MTWAI < 3).29 To 
allow using IBD activity measures (MTWAI for 
UC patients and CDAI for CD patients) in a sin-
gle model, we used Z-Score transformed values of 
MTWAI and CDAI. MTWAI and CDAI values 
were Z-score transformed to allow using both 
parameters in the same figure.
Results
Clinical characteristics at diagnosis, at therapy 
start, or at enrollment
Figure 1 shows the flow of patient recruitment for 
this study. A total of 581 patients were included in 
our observational analysis (113 in group A, 193 in 
group B, 275 in group C). The main baseline char-
acteristics are shown in Table 1. CD was more 
frequent in group B (anti-TNF therapy± immu-
nomodulatory therapy) than in group A 
Therapeutic Advances in Gastroenterology 14
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(immunomodulatory therapy) and least frequent in 
group C (control group). Further, patients in group 
B were younger at diagnosis and patients in group 
C were oldest at the start of observation (Table 1).
Most sociodemographic characteristics at base-
line including education, smoking, break up of a 
relationship, and level of employment were dis-
tributed evenly between groups (Supplemental 
Table S1); however, absence from work was 
reported most frequently by patients in group B 
(p < 0.001). Within group B, absence from work 
was correlated significantly with increased depres-
sive symptoms at 1 year after therapy start 
(r = 0.15), but not at the other three time points 
assessed. Absence from work showed no signifi-
cant association with anxiety symptoms at any 
time point.
Levels of anxiety (HADS-A) were similar in all 
three groups (Table 2) but depressive symp-
toms before therapy were higher in group B 
(p < 0.001).
Clinical characteristics during follow up
Patients were followed for up to 5 years 
(Supplemental Table S3). Some patients in all 
groups experienced active disease (CDAI > 150, 
MTWAI ⩾ 3), with the lowest percentage of dis-
ease activity in group C and the highest percent-
age of disease activity in group A [66.9% versus 
74.3%, non-significant (n.s.)] during follow up. 
Further, a considerable fraction of patients in all 
groups were treated with steroids. As expected, 
rates of steroid treatment were significantly higher 
in group A (60.2%) and groups B (62.2%) 
Figure 1. Flow chart of patient selection.
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compared with groups C (26.5%, p < 0.001) with 
more severe disease and more disease exacerba-
tions in patients of group A and B. A substantial 
fraction of patients also experienced extra 
intestinal manifestation (EIM), complications, 
perianal fistula and/or abscess or stenosis, or sur-
gery with the lowest morbidity in group B 
(p < 0.001).
Table 1. Baseline clinical characteristics of patient groups.
Group A Group B Group C Total p value
Number of patients (%) 113 (19.5) 193 (33.2) 275 (47.3) 581 (100)  
Gender (%)
 Male 61 (54.0) 101 (52.3) 129 (46.9) 291 (50.1) 0.335
 Female 52 (46.0) 92 (47.7) 146 (53.1) 290 (49.9)
Initial diagnosis (%)
 Crohn 53 (46.9) 124 (64.2) 72 (26.2) 249 (42.9) <0.001
 UC/IBD unclassified 60 (53.1) 69 (35.8) 203 (73.8) 332 (57.1)
Age at diagnosis









Age at therapy start (or at 
enrollment)









Disease duration until therapy or 
enrollment










 L1 (ileum) (%) 13 (24.5) 26 (23.2) 20 (30.8) 59 (25.6) 0.58
 L2 (colon) (%) 11 (20.8) 21 (18.7) 16 (24.6) 48 (20.9)
 L3 (ileum and colon) (%) 27 (50.9) 62 (55.4) 29 (44.6) 118 (50.3)
 L4 (upper GI only) (%) 2 (3.8) 3 (2.7) 0 (0.0) 5 (2.2)
 Missing or unknown 0 12 7 19
Initial UC location
 Proctitis (%) 8 (13.6) 11 (18.3) 70 (38.5) 89 (29.6) <0.001
 Left-sided colitis (%) 21 (35.6) 21 (35.0) 63 (34.6) 105 (34.9)
 Pancolitis (%) 30 (50.8) 28 (46.7) 49 (26.9) 107 (35.5)
 Missing or unknown 1 9 21 31
Values reflect absolute numbers with percentage in parentheses. 
Bold entries indicate statistical significance.
GI, gastrointestinal; IBD, inflammatory bowel diseases; UC, ulcerative colitis.
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Table 2. Psychiatric morbidity of patients at baseline and during follow up. Anxiety is shown as HADS-A, depressive symptoms as 
HADS-D scores.
Group A Group B Group C Total p value
Number of patients (%) 113 (19.5) 193 (33.2) 275 (47.3) 581 (100)  
Rates of 5-ASA ANXIETY (%) 90 (79.6) 147 (76.2) 248 (90.2) 485 (83.5) <0.001
Before therapy
 Median, q25–q75, min–max, n 5.5, 3–8.5, 0–20, 
n = 112
6, 3–9, 0–18, 
n = 177
5, 3–8, 0–19, 
n = 266




 Median, q25–q75, min–max, n 5, 3–8, 0–17, 
n = 109
5, 2–7, 0–18, 
n = 170
5, 2–7, 0–20, 
n = 260




 Median, q25–q75, min–max, n 5, 2.3–8, 0–17, 
n = 94
5, 3–8, 0–16, 
n = 123
5, 2–8, 0–16, 
n = 216




 Median, q25–q75, min–max, n 4, 2–7, 0–18, 
n = 63
5, 3–9, 0–19, 
n = 90
5, 2–7, 0–18, 
n = 150
5, 2–8, 0–19, 
n = 303
0.312
p value before versus 1 years 0.775 0.032 0.252 0.032
p value before versus 3 years 0.197 0.277 0.509 0.092
p value before versus 5 years 0.224 0.663 0.222 0.091
Depression
Before therapy
  Median, q25–q75, min–max, n 3.5, 1–7, 0–17, 
n = 112
4, 1–7, 0–15, 
n = 177
2, 1–4, 0–17, 
n = 266




  Median, q25–q75, min–max, n 2, 1–6, 0–17, 
n = 109
2, 1–6, 0–16, 
n = 170
2, 0–4.3, 0–18, 
n = 260
2, 0–5, 0–18. 
n = 539
0.097
 After 3 years
  Median, q25–q75, min–max, n 2, 0–6, 0–18, 
n = 94
3, 1–6, 0–15, 
n = 123
2, 0.5–4, 0–17, 
n = 216
2, 1–5, 0–18, 
n = 433
0.062
 After 5 years
  Median, q25–q75, min–max, n 2, 1–5, 0–20, 
n = 63
3, 1–7, 0–17, 
n = 89
1, 0–5, 0–20, 
n = 150
2, 0–5, 0–20, 
n = 302
0.075
 p value before versus 1 year 0.039 0.005 0.347 0.001
 p value before versus 3 years 0.068 0.052 0.529 0.011
 p value before versus 5 years 0.051 0.182 0.275 0.012
Values reflect median with IQR. 
Bold entries indicate statistical significance.
5-ASA, 5-aminosalicylate; HADS, hospital anxiety and depression scale ; IQR, interquartile range.
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Anxiety and depressive symptoms tended to 
decrease in all patient groups over the 5-year 
observa tion period (Table 2, Supplemental 
Figure S1); a significant improvement was seen at 
1-year follow up in group B for anxiety and depres-
sion and in group A for depressive symptoms.
Multivariable model to capture effects of 
treatment on anxiety and depressive symptoms
To identify potential time-dependent effects 
of treatment in our heterogeneous patient popu-
lation, a mixed effects model was built, 
accounting for short-term and long-term effects 
of treatment as well as individual patient baseline 
values for anxiety and depressive symptoms and 
individual trends in patients. Two separate mod-
els, for anxiety and depression, respectively, were 
built, with and without adjustment for potential 
confounders (Table 3, Figure 2).
Within the first 2.5 years after start of therapy, 
Group B (anti-TNF therapy ± immuno-modula-
tory therapy) was associated with an improvement 
of symptoms (anxiety: improvement of HADS-A 
by 0.712 points per year, p = 0.001; depressive 
Table 3. Linear mixed model for treatment effects on anxiety and depressive symptoms. Values reflect 
regression coefficient B with 95% CI.
Linear mixed model for anxiety Linear mixed model for 
depression
Coefficient (95% CI; p value)
Fixed effects
 Intercept (β0) 5.437 (5.012–5.862; <0.001) 2.961 (2.577–3.345; <0.001)
 z-score of initial disease activity 0.297 (0.048–0.546; 0.019) 0.563 (0.332–0.794; <0.001)
 Time (β1) −0.066 (−0.147 to 0.015; 0.108) 0.001 (−0.078 to 0.078; 0.998)
  Short-terma time effect after  
imm.-mod. therapy (β1 + β2)
−0.291 (−0.789 to 0.208; 0.253) −0.664 (−1.132 to −0.196; 0.005)
  Long-terma time effect after  
imm.-mod. therapy (β1 + β3)
−0.148 (−0.284 to −0.013; 0.032) −0.147 (−0.278 to −0.017; 0.027)
  Short-terma time effect after  
anti-TNF therapy (β1 + β4)
−0.712 (−1.147 to −0.277; 0.001) −0.737 (−1.146 to −0.329; <0.001)
  Long-terma time effect after  
anti-TNF therapy (β1 + β5)
−0.132 (−0.242 to −0.022; 0.018) −0.127 (−0.233 to −0.020; 0.020)
 Being in Group A (β6) 0.504 (−0.337 to 1.345; 0.240) 1.060 (0.300–1.820; 0.006)
 Being in Group B (β7) 0.452 (−0.272 to 1.176; 0.221) 1.077 (0.424–1.731; 0.001)
Random effects
  SD for the intercept 
([[IMG]]10.1177_175628482 
11033763-ineq1.eps[[/IMG]]
3.098 (2.868–3.347) 2.759 (2.547–2.988)
  SD for the slope 
([[IMG]]10.1177_175628482 
11033763-ineq2.eps[[/IMG]])
0.224 (0.129–0.389) 0.241 (0.158–0.370)
 Correlation between X and Y −0.095 (−0.366 to 0.192) 0.184 (−0.144 to 0.476)
aShort-term (⩽2.5 years) and long-term effects (>2.5 years) according to therapy. 
Bold entries indicate statistical significance.
CI, confidence interval; imm.-mod., immuno-modulatory; SD, standard deviation; TNF tumor necrosis factor.
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symptoms: improvement of HADS-D by 0.737 
points per year, p < 0.001). After 2.5 years, psychi-
atric symptoms continued to improve signifi-
cantly, even though at a lower rate (anxiety: 0.132 
points improvement per year, p = 0.018; depres-
sive symptoms: 0.127 improvement per year, 
p = 0.020). For immunomodulatory therapy, simi-
lar trends were observed, although anxiety 
improved significantly only after 2.5 years. The 
magnitude of a significant improvement was simi-
lar in group A and B (Table 3, Figure 2).
Corrected multivariable model to  
capture effects of treatment on anxiety  
and depressive symptoms
To assess robustness of our findings, we included 
potential confounders in our model (Table 4), cor-
recting for age, disease duration, diagnosis, steroid 
intake, complications, EIM, surgery, fistula, steno-
sis, smoking, absence from work, education level, 
and stressful life events (break-up in a relationship).
Even after correction for confounders, effects of 
treatment on anxiety and depressive symptoms 
remained robust with a treatment-related 
improve ment in both anxiety and depressive 
symptoms within the first 2.5 years and also after 
2.5 years in group B. Similarly, for group A, cor-
recting for confounders yielded long-term 
improvement of anxiety and both short-term and 
long-term improvement in depressive symptoms.
Depressive symptoms also significantly improved 
in patients working during follow up and, addi-
tionally, in those with fistula/abscess.
Multivariable model to capture effects of 
treatment on disease activity
Parallel to improvements in depressive symptoms 
and anxiety, treatment with either anti-TNF 
therapy or immunomodulators reduced disease 
activity within the first year and after 2.5 years, 
with weaker effects beyond 2.5 years. For disease 
Figure 2. Trends for anxiety and depressive symptoms over time in a mixed model. Our mixed model 
distinguishes the first 2.5 years after start of therapy and the time following it. The blue line indicates the 
average evolution of depression. Red lines indicate the margins of error: trajectories of patients will be 
situated in the zone between red lines with a statistical probability of 95%. (a) Model of evolution of anxiety in 
Group A; (b) Model of evolution of anxiety in Group B; (c) Model of evolution of depressive symptoms in Group 
A; (d) Model of evolution of depressive symptoms in Group B.
HADS, hospital anxiety and depression scale; TNF, tumor necrosis factor.
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Table 4. Linear mixed model for treatment effects on anxiety and depressive symptoms, corrected for 
confounders. Values reflect regression coefficient B with 95% CI.
Linear mixed model for anxiety 
with confounders
Linear mixed model for 
depressive symptoms with 
confounders
Coefficient (95% CI; p value)
Fixed effects
 Intercept (β0) 6.265 (4.411–8.119; <0.001) 4.322 (2.618–6.025; <0.001)
 z-score of initial disease activity 0.285 (0.009–0.560; 0.043) 0.481 (0.227–0.734; <0.001)
 Time (β1) −0.080 (−0.162 to 0.002; 0.056) −0.012 (−0.091 to 0.068; 0.771)
  Short-terma time effect after  
imm.-mod. therapy (β1 + β2)
−0.264 (−0.766 to 0.238; 0.303) −0.680 (−1.154 to −0.206; 0.005)
  Long-terma time effect after  
imm.-mod. therapy (β1 + β3)
−0.158 (−0.296 to −0.020; 0.025) −0.153 (−0.286 to −0.019; 0.025)
  Short-terma time effect after  
anti-TNF therapy (β1 + β4)
−0.825 (−1.274 to −0.375; <0.001) −0.826 (−1.251 to −0.401; <0.001)
  Long-terma time effect after  
anti-TNF therapy (β1 + β5)
−0.128 (−0.241 to −0.016; 0.026) −0.131 (−0.241 to −0.022; 0.019)
 Being in Group A (β6) 0.644 (−0.266 to 1.553; 0.166) 1.226 (0.402–2.050; 0.004)
 Being in Group B (β7) 0.447 (−0.403 to 1.297; 0.303) 1.031 (0.260–1.802; 0.009)
 Gender: female (male 0 = ref) 1.065 (0.487–1.643; <0.001) 0.133 (−0.399 to 0.665; 0.624)
 Age −0.024 (−0.049 to 0.002; 0.067) 0.001 (−0.023 to 0.024; 0.977)
 Disease duration 0.001 (−0.033 to 0.035; 0.950) 0.006 (−0.025 to 0.037; 0.709)
 Initial diagnosis (ref: CD) 0.139 (−0.593 to 0.872; 0.709) −0.509 (−1.183 to 0.165; 0.139)
  Steroid intake during therapy or 
follow up (ref: no)
−0.386 (−1.001 to 0.229; 0.219) 0.025 (−0.541 to 0.591; 0.931)
  Complication during therapy or 
follow up
−0.160 (−0.784 to 0.463; 0.614) 0.081 (−0.493 to 0.655; 0.782)
 EIM during therapy or follow up 0.771 (0.179–1.363; 0.011) 0.413 (−0.132 to 0.958; 0.138)
  Surgery during therapy or  
follow-up
0.473 (−0.259 to 1.206; 0.205) 0.612 (−0.062 to 1.286; 0.075)
  Fistula/abscess during therapy 
or follow up
−0.624 (−1.429 to 0.181; 0.129) −0.929 (−1.671 to −0.187; 0.014)
  Stenosis during therapy or  
follow up
−0.186 (−1.033 to 0.661; 0.666) −0.589 (−1.369 to 0.190; 0.138)
  Used to smoke during therapy 
or follow up
0.694 (0.064–1.323; 0.031) 0.300 (−0.279 to 0.880; 0.310)
  Worker during therapy or  
follow up
−1.043 (−1.920 to −0.165; 0.020) −1.820 (−2.628 to −1.012; <0.001)
(Continued)
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activity, improvements in group A and group B 
were similar (Supplemental Figure S2, Supple-
mental Table S2).
Discussion
We found a significant decrease in depression in 
patients treated with TNF inhibitors or immune 
modulators compared with no therapy during 
the first 2.5 years of treatment. TNF inhibitor 
treatment was also associated with an improve-
ment in anxiety within the first 2.5 years. Both 
depression and anxiety continued to improve 
beyond 2.5 years, but at lower rates. Symptoms 
of anxiety and depression tended to decrease in 
all patient groups and a significant improvement 
was seen at the 1-year follow-up in group B for 
anxiety and depressive symptoms and in group A 
for depressive symptoms. To our knowledge, this 
is the first longitudinal analysis on the course of 
anxiety and depressive symptoms across several 
time points in a large sample of an IBD cohort. 
Our findings are in line with results from a 
previously published smaller observational study 
Lix et al.30
The frequency of psychiatric conditions is 
increased in patients with IBD with a reported 
prevalence of depression and anxiety of 21–31% 
and 26–30%, respectively.17,31,32 In active IBD, 
psychiatric symptoms are more prevalent than in 
quiescent disease.32 Therefore, it is important to 
understand whether IBD treatment with TNF-
inhibitors or immune modulators will improve or 
worsen pre-existing anxiety or depression in IBD 
patients. Detection of significant effects required 
a linear mixed effects models regression analysis 
accounting for group differences and random 
effects. Of note, these differences did not reach 
significance in our direct group comparison 
(Table 2), most likely due to the high variance.
Baseline disease parameters differed between treat-
ment groups and factors like a diagnosis of CD, 
disease location and extend of disease, as well 
longer disease duration, previous surgeries, fistulas, 
Linear mixed model for anxiety 
with confounders
Linear mixed model for 
depressive symptoms with 
confounders
Coefficient (95% CI; p value)
  Absent from work at least once 
during therapy or follow up
0.316 (−0.373 to 1.005; 0.368) 0.573 (−0.060 to 1.207; 0.076)
 Educational level: low 0 (ref) 0 (ref.)
 Educational level: middle −0.283 (−1.036 to 0.470; 0.462) −0.605 (−1.298 to 0.088; 0.087)
 Educational level: high −0.028 (−0.674 to 0.618; 0.932) 0.076 (−0.519 to 0.670; 0.803)
 Break-up during therapy or 
follow-up
0.425 (−0.511 to 1.360; 0.374) −0.255 (−1.117 to 0.606; 0.561)
Random effects
  SD for the intercept 
([[IMG]]10.1177_175628482 
11033763-ineq3.eps[[/IMG]]
2.998 (2.766–3.249) 2.656 (2.444–2.887)
  SD for the slope 
([[IMG]]10.1177_175628482 
11033763-ineq4.eps[[/IMG]])
0.234 (0.141–0.389) 0.250 (0.167–0.374)
 Correlation between X and Y −0.141 (−0.401 to 0.140) 0.077 (−0.220 to 0.361)
aShort-term (⩽2.5 years) and long-term (>2.5 years) effects according to therapy. 
Bold entries indicate statistical significance.
CD, Crohn’s disease; CI, confidence interval; EIM, extra intestinal manifestation; SD, standard deviation.
Table 4. (Continued)
AR Siebenhüner, JB Rossel et al.
journals.sagepub.com/home/tag 11
or EIM were associated with higher use of anti-
TNF therapy or immunomodulatory therapy. 
However, anti-TNF therapy and/or immunomod-
ulatory therapy remained robust predictors for 
patients’ mood in a corrected multivariable analysis 
considering sociodemographic variables and IBD-
specific variables, including therapy with corticos-
teroids, which was allowed in every group (Table 4). 
Therefore, our combined analysis suggests an asso-
ciation of anti-TNF therapy and immunomodula-
tory therapy with improvements in mood. But we 
could not distinguish if anti-TNF would have a 
direct or indirect effect on changes in mood.
There are only few studies to date investigating 
the effect of anti-TNF treatment and immu-
nomodulatory therapy on mood in patients with 
IBD. As in our study, all previous studies are 
observational in nature. Choi et al. performed a 
nation-wide population based cohort study in 
South Korea and followed 15,569 IBD patients 
and 46,707 controls over a mean of 6 years and 
observed a HR of 1.6 due to IBD for the onset of 
anxiety and a HR of 2 for depressive symptoms, 
respectively.9 However, therapy with anti-TNF or 
immunomodulatory treatment protected patients 
from both conditions.9 In another cross-sectional 
analysis with 120 IBD patients, individuals with 
depressive symptoms were more likely to have 
active disease; however, use of anti-TNF therapy 
was negatively associated with depressive symp-
toms (11.5% anti-TNF-treatment in depressed 
patients versus 42.3% without depressive symp-
toms33). In another observational study with 160 
IBD patients with moderate-to-severe disease, 
resolution of anxiety and depressive symptoms at 
week 6 after start of treatment was similar upon 
treatment with anti-TNFs and vedolizumab.34
Overall, these results, as well as our data, confirm 
that effective anti-inflammatory treatment is able to 
treat both bowel inflammation and psychiatric symp-
toms. However, it should be noted that, in rare cases, 
depressive symptoms and even suicidal behavior has 
been associated with anti-TNF therapy.35
The SIBDCS did not systematically assess circu-
lating inflammatory markers like C-reactive pro-
tein (CRP) and TNF. Therefore, we could not 
test whether systemic inflammation can induce 
depressive symptoms as previously suggested for 
inflammatory somatic diseases,36 including 
IBD.37 In line with these observations, in CD 
patients, depressive symptoms were associated 
with different cytokine profiles and macrophage 
differentiation patterns.38 Another, albeit related, 
theory posits that inflammation triggers sickness 
behavior that is characterized not only by depres-
sion-like behaviors but also anxiety,39 wherein 
TNF may play a paramount role.40 Therefore, a 
gut–brain axis might impact on the outcome 
of anxiety and depressive symptoms in IBD 
patients.41
Strengths of our study include a sample size of 
more than 570 patients and the longitudinal 
design with a follow-up time of several years with 
sequential HADS measurements. Further, our 
multivariable analysis accounts for a range of 
potentially important confounding variables. One 
limitation is our lack of information about the 
duration of active disease phases and the cumula-
tive exposure to inflammation. Another limitation 
is a potential selection bias for higher anxiety and 
depressive symptom scores due to a higher pro-
portion of UC/IBD unclassified and proctitis in 
the group receiving neither anti-TNF therapy 
nor IM compared with the other two treatment 
groups. Moreover, exact dosages of anti-TNFs 
and immunomodulatory therapy and trough or 
drug levels are unknown. In addition, patient’s 
compliance could not be assessed reliably due to 
a lack of information regarding drug prescriptions 
and dispensing, a common shortcoming of cohort 
studies. Regarding steroid treatment the SIBDC 
data base lacks specific information on tapered 
dosages and cumulative dosages over time. 
Therefore, and as a limitation, rates of “steroid 
treatment” (i.e., any usage of peroral or intrave-
nous steroids) is the best surrogate we can pro-
vide. The absence of a quantitative variable for 
steroid use and other covariates, as well as the 
lack of time-dependent variables, are further limi-
tations of our study. Furthermore, we cannot 
exclude the possibility that, in group B, combined 
therapy with anti-TNF therapy with immu-
nomodulatory therapy had a different effect than 
anti-TNF treatment alone. Instead of a clinical 
interview, anxiety and depressive symptoms were 
assessed with a self-rated instrument. Regarding 
the mechanism of improvements in depressive 
symptoms, our study does not distinguish direct 
effects of anti-TNF therapy on mood from indi-
rect effects on mood via treatment of the under-
lying IBD. However, our models have been 
corrected for disease activity. This means that 
the observed effects were present even after the 
correction for the fact that some patients in group 
Therapeutic Advances in Gastroenterology 14
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A and B did not reach a remission, whereas others 
in these groups did. Unfortunately, a dedicated 
subanalysis limited to patients with clear remis-
sion and patients with persistent inflammation 
over several years was not possible since only a 
minority of patients would have been eligible for 
such a subgroup analysis. Lastly, our results are 
based on longitudinal observations and cannot 
claim causality for effects of anti-TNF treatment 
and/or immunomodulatory therapy on mood. 
For this, in future randomized controlled trials, 
anxiety and depressive symptoms should be con-
sistently addressed as secondary outcomes.
Taken together, anti-TNF treatment and immu-
nomodulatory therapy affect patient’s mood with 
strongest improvement seen within the first 
2.5 years of therapy. Therefore, in case of active 
IBD the responsible physician should also inquire 
about anxiety and/or depressive symptoms, since 
efficient IBD treatment might improve both gas-
trointestinal and psychiatric symptoms. Our study 
does not allow a statement as to whether the 
improvement in mood occurred directly via medi-
cation effects on inflammation-driven neurobe-
havioral processes or indirectly via a reduction in 
disease activity.6,42 Moreover, in future rand-
omized controlled trials for IBD treatment, mood 
should consistently be considered as secondary 
outcome.
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